Results of the Myeloproliferative Neoplasms - Research Consortium (MPN-RC) 112 Randomized Trial of Pegylated Interferon Alfa-2a (PEG) Versus Hydroxyurea (HU) Therapy for the Treatment of High Risk Polycythemia Vera (PV) and High Risk Essential Thrombocythemia (ET)
John Mascarenhas(Tisch Hospital), Robert S. Hoffman(New York City Department of Health and Mental Hygiene), Murat O. Arcasoy(Duke University), Lonette Sandy(Icahn School of Medicine at Mount Sinai), Adam J. Mead(National Institute for Health and Care Research), Damiano Rondelli(University of Illinois Chicago), Mohamed E. Salama(The University of Texas at San Antonio Health Science Center), Craig M. Kessler(Georgetown University), Heidi Kosiorek(Mayo Clinic in Florida), Ruben A. Mesa(Atrium Health Wake Forest Baptist), Richard T. Silver(Cornell University), Josef T. Prchal(Huntsman Cancer Institute), Vesna Najfeld, Alessandro M. Vannucchi(Azienda Ospedaliero-Universitaria Careggi), Claire Harrison(Guy's and St Thomas' NHS Foundation Trust), Rona Singer Weinberg(University of North Carolina at Chapel Hill), Joseph Tripodi(Icahn School of Medicine at Mount Sinai), Casey L. O’Connell(University of Southern California), Valerio De Stefano(Agostino Gemelli University Polyclinic), Alessandro Rambaldi(Ospedale Papa Giovanni XXIII), Arnon Nagler(Sheba Medical Center), Marina Kremyanskaya(Tisch Cancer Institute), D Leibowitz(Sutter Health), Abdulraheem Yacoub(The University of Kansas Cancer Center), Mary Frances McMullin(Queen's University Belfast), Raajit K. Rampal(Memorial Sloan Kettering Cancer Center), Leah Price(Cwm Taf University Health Board), Rosalind Catchatourian(John H. Stroger, Jr. Hospital of Cook County), Amylou C. Dueck(Mayo Clinic in Arizona), Andrea Bacigalupo(Università Cattolica del Sacro Cuore), Joanne Ewing(Heart of England NHS Foundation Trust), Elliott F. Winton(Emory University), Judith D. Goldberg(New York University), Dmitriy Berenzon(Atrium Health Wake Forest Baptist), Jean‐Jacques Kiladjian(Délégation Paris 5)
Cited by 45
Related Papers
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis
|Cancer Cell|2005|3k
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.8k
Symptom Monitoring With Patient-Reported Outcomes During Routine Cancer Treatment: A Randomized Controlled Trial
|Journal of Clinical Oncology|2015|2.6k